Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BR101801 |
Synonyms | |
Therapy Description |
BR101801 inhibits PIK3CG, PIK3CD, and PRKDC (DNA-PK), which potentially leads to decreased proliferation and increased apoptosis of tumor cells and reduced tumor growth (PMID: 34873471, PMID: 36895970). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BR101801 | BR 101801|BR-101801 | DNA_PK Inhibitor 9 PIK3CD inhibitor 27 PIK3CG inhibitor 10 | BR101801 inhibits PIK3CG, PIK3CD, and PRKDC (DNA-PK), which potentially leads to decreased proliferation and increased apoptosis of tumor cells and reduced tumor growth (PMID: 34873471, PMID: 36895970). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04018248 | Phase I | BR101801 | BR101801 in Adult Patients With Advanced Hematologic Malignancies( Phase I) | Active, not recruiting | USA | 1 |